ModifiedUnitedHealthcarePolicy 2025 P 1057-15

Javygtor™ (sapropterin dihydrochloride), Kuvan® (sapropterin dihydrochloride), sapropterin dihydrochloride, Zelvysia (sapropterin dihydrochloride) - Prior Authorization/Notification - UnitedHealthcare

Prior authorization/notification policy for Javygtor, Kuvan, generic sapropterin dihydrochloride, and Zelvysia for treatment of phenylketonuria (PKU) / hyperphenylalaninemia (HPA) in eligible members; defines initial and reauthorization clinical criteria, combination exclusions, authorization duration, and program notes.

Policy Summary

PayerUnitedHealthcare

PolicyJavygtor™ (sapropterin dihydrochloride), Kuvan® (sapropterin dihydrochloride), sapropterin dihydrochloride, Zelvysia (sapropterin dihydrochloride) - Prior Authorization/Notification

Policy CodePolicy 2025 P 1057-15

Change TypeAdded drugsupdated exclusions and authorization duration

Effective DateFeb 1, 2026

Next Review Date

Key ActionInitial and reauthorization approvals require meeting the listed clinical criteria; authorization will be issued for 12 months.

SourceLink

POLICY UPDATE CHANGES

Added Zelvysia to program.

Added Javygtor to program (3/2023).

Updated authorization approval duration to 12 months (3/2024).

Annual reviews and reference updates through 2025 with P&T approvals; effective date set to 2026-02-01.

3Product Names Covered

12 moAuthorization Duration

2Combination Therapies Excluded

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Sapropterin dihydrochloride products (Javygtor, Kuvan, Zelvysia) are phenylalanine hydroxylase activators indicated for reducing blood phenylalanine in patients one month of age and older with hyperphenylalaninemia (HPA) due to BH4-responsive phenylketonuria (PKU) and are used with a Phe-restricted diet. This policy (Policy Number: 2025 P 1057-15) is a prior authorization/notification program administered by UnitedHealthcare and covers Javygtor, Kuvan, generic sapropterin dihydrochloride, and Zelvysia with clinical criteria for initial and reauthorization approvals.

Coverage is prior-authorization based. Initial and reauthorization approvals require meeting the specified clinical criteria (diagnosis, diet status, and combination therapy exclusions) and authorizations will be issued for 12 months. Refer to plan-specific information for brand exclusion details and automated approval processes.

Thresholds & Quick Facts

Authorization duration12 months

Product Names CoveredJavygtor; Kuvan; Zelvysia (3)

Combination therapies excludedPalynziq (pegvaliase-pqpz); Sephience (sepiapterin) (2)

Brand exclusion noteBrand Kuvan and Javygtor may be excluded for some plans; refer to plan specifics

Effective date2026-02-01

Last review2025-11-01

Initial Therapy Criteria

Initial Authorization

Approved when ALL of the following are met:

Diagnosis of phenylketonuria (PKU)
Diet: Patient is actively on a Phe-restricted diet
Phe-restricted diet required as concomitant therapy
Combination exclusion: Patient is not receiving the requested medication in combination with Palynziq (pegvaliase-pqpz) or Sephience (sepiapterin)
Claims will not be approved for combination use

ref

Continuation / Reauthorization Criteria

Reauthorization

Approved when ALL of the following are met:

Diet: Patient is actively on a Phe-restricted diet
Baseline defined by prior measurement
Clinical response: Blood Phe levels continue to remain lower than baseline levelLower than Baseline
Baseline = pre-treatment blood phenylalanine level used as comparator for reauthorization response
Combination exclusion: Patient is not receiving the requested medication in combination with Palynziq (pegvaliase-pqpz) or Sephience (sepiapterin)

Unproven / Exclusions

Combination use of sapropterin products with certain other therapies is explicitly prohibited. Claims will not be approved if the patient is receiving the requested sapropterin product in combination with Palynziq (pegvaliase-pqpz) or Sephience (sepiapterin).

Brand-specific guidance: Javygtor and Brand Kuvan are typically excluded from coverage for many plans; refer to plan-specific exclusion status and tried/failed criteria where applicable. Plan-specific exclusions and federal/state mandates may further affect coverage.

Applicable Codes

drugs covered by policy (by name)mixedCovered

Javygtor	sapropterin dihydrochloride
Kuvan	sapropterin dihydrochloride
Zelvysia	sapropterin dihydrochloride
sapropterin dihydrochloride	generic/unspecified

combination therapies explicitly excludedmixedNot Covered

Palynziq	pegvaliase-pqpz (combination use not permitted)
Sephience	sepiapterin (combination use not permitted)

brand-specific coverage notesmixedNot Covered

Brand Kuvan	typically excluded from coverage; plan-specific exclusion may apply
Javygtor (brand)	typically excluded from coverage for some plans (refer to plan specifics)

Provider Actions & Prior Authorization

Prior Authorization

Prior authorization required

Initial and reauthorization approvals require meeting the listed clinical criteria; authorization will be issued for 12 months.

Authorization duration: 12 months

Documentation Required

Clinical documentation for reauthorization

Provide evidence that blood phenylalanine (Phe) levels remain lower than baseline and documentation that patient remains on a Phe-restricted diet.

Denial Risk

Clinical Evidence & References

Key references include the package inserts and guideline cited in the program references: Kuvan [package insert] (August 2024), Javygtor [package insert] (October 2024), Zelvysia [package insert] (April 2025), and the 2023 ACMG guideline (published 2025) on phenylalanine hydroxylase deficiency diagnosis and management.

Background

Sapropterin dihydrochloride products (Javygtor, Kuvan, Zelvysia) are indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with HPA due to BH4-responsive PKU. These agents are intended to be used in conjunction with a Phe-restricted diet as part of management.

Phe-restricted diet: A diet limiting phenylalanine intake; required concomitant therapy for sapropterin products and must be active for initial and reauthorization approvals.

Baseline: Pre-treatment blood phenylalanine level used as the comparator for assessing response at reauthorization; reauthorization requires documentation that blood Phe levels remain lower than this baseline.

Revision History

3/2023addition

Javygtor was added to the program; exclusion footnote and references were updated.

3/2024policy_revision

Authorization approval duration updated to 12 months (reauthorization/initial authorization set to 12 months).

11/2025addition

Zelvysia was added to the program and Sephience was added to the combination-use exclusion criteria.